Veredus Laboratories’ VereCoV Detection Kit receives Singapore HSA Provisional Authorisation for IVD use

Singapore, February 27, 2020 – Veredus Laboratories Pte Ltd “Veredus” has obtained the Provisional Authorisation from Singapore Health Sciences Authority (HSA) for its VereCoV™ Detection Kit following Veredus’ rapid launch of this kit as a “Research Use Only” (RUO) test earlier this year. With this Authorisation, VereCoV™ Detection Kit can be used directly by laboratories or hospitals to test patients for clinical diagnosis.

As a multiplex RT-PCR and microarray-based test, VereCoV™ Detection Kit integrates an ultra-fast miniaturised PCR reactor for the amplification of nucleic acids and a customised microarray to qualitatively detect 2019 novel coronavirus (2019-nCoV) with the additional capability of detecting a subset of Severe Acute Respiratory Syndrome (SARS-CoV) simultaneously within the same test. This allows users whom are operating in real-world situations, to apply the full benefit of molecular testing, at a fraction of the time, cost and complexity.

The VereCoV™ Detection Kit is a collaborative effort between Veredus and the Home Team Science and Technology Agency (HTX) Chemical, Biological, Radiology, Nuclear and Explosives (CBRNE) Centre of Expertise.

“The test kit is designed with the capability to detect COVID-19 with high specificity and sensitivity, similar to how a key with a specific design will be able to open the corresponding lock,” said Ms Ong Bee Leng, Director of the HTX CBRNE Centre of Expertise. She added, “We are pleased to partner with Veredus in such a crucial time to collaborate on an innovative solution to detect COVID-19 for our national interest and to support the global need to prevent the further spread of the virus.”

“As highlighted in our last press release, the commercial launch of the VereCoV™ Detection Kit signifies a breakthrough in the detection of 2019- nCoV and SARS-CoV.” said Dr Rosemary Tan, CEO of Veredus Laboratories. “Naturally, the next critical step would be for our kit to play an important role in the clinical diagnosis of COVID-19 within the healthcare community.”

For more information on the product, please contact: Dr Damian Foo, Product Manager Veredus Laboratories Pte Ltd Email: damian.foo@vereduslabs.com Mobile: +65 9649 0569

About Veredus Laboratories Pte Ltd Veredus was founded in 2003 and launched its first products in 2005. Veredus manufactures, markets and sells VerePLEX™ Biosystem to provide innovative multiplexed molecular solutions in the food safety, biosurveilance, infectious disease and custom testing markets. The VerePLEX™ Biosystem works in conjunction with VereChip™ - a Lab-onChip platform that combines Micro-Electro-MechanicalSystems (MEMS) with micro-fluidics to integrate multiplexed nucleic acid amplification with microarray detection for rapid, cost-effective, and accurate analysis of biological materials. Veredus Laboratories is now a wholly-owned subsidiary of Sekisui Chemical Co., Ltd.

About HTX HTX is the first of its kind Science and Technology Agency in the world that brings together science and engineering capabilities across the Home Team Departments to transform the homeland security landscape and keep Singapore safe. They focus on such areas as biometrics, chemical, biological, radiological, nuclear and explosives threats, cybersecurity, artificial intelligence, forensics, robotics, automation and unmanned systems, and surveillance. With the engagement in research or ground operations, HTX is well-positioned to deliver cutting edge technologies that will empower the Home Team to solve crimes, save lives, secure borders and safeguard Singapore’s public spaces. Beyond technologies and solutions, the goal of HTX is to facilitate greater cooperation and synergy across the entire homeland security ecosystem, and enable the Home Team Departments to adopt a unified approach in a common mission to secure Singapore as the safest place on planet earth.

Did you like this article?